Navigation Links
UC Davis bench-to-bedside research: Promising treatment in clinical trials
Date:3/26/2009

occur together and a new class of drugs that addresses both is very attractive."

Cardiologist and cell biologist Nipavan Chiamvimonvat of the UC Davis Health System and a longtime collaborator with Hammock, said many diseases tend to occur together in vascular biology. "So, a compound that addresses heart failure, as we have shown, combined with the reduction of blood pressure, inflammation and diabetes is very attractive."

The Phase IIa clinical trial is a double-blind, placebo-controlled study. Officials will enroll a total of 150 patients with impaired glucose tolerance, mild obesity and mild to moderate hypertension.

Each patient will receive 28 days of treatment. The AR9281 enzyme inhibitor will be studied for safety, tolerability, reduction of blood pressure and various measures of glucose and lipid metabolism. Results are expected the first quarter of 2010.

The winding, twisting path that took Hammock from his lab, to collaborative research with other UC Davis scientists, to his founding of a $50 million-investment biotechnology company, to clinical trials proved as steep as the mountains he climbs.

Tracing the events that led to the discovery of the enzyme, Hammock recalled doing research at UC Berkeley four decades ago with then-colleague Sarjeet Gill. Gill discovered the enzyme in mammals. Shortly after Hammock found the novel enzyme in insects.

"Both of us have been chipping away at this problem ever since," Hammock said. "By 1975 we were convinced that this was a therapeutic target but no one else was. When we finally found potent inhibitors for the enzyme that worked in whole animals, we had a tool to demonstrate that this was a promising therapeutic target."

Hammock was initially interested in regulating the development of insect larvae. With the discovery of the enzyme inhibitor, however, he switched part of his research from "pest control to pain control."

At the onset,
'/>"/>

Contact: Kathy Keatley Garvey
kegarvey@ucdavis.edu
530-754-6894
University of California - Davis
Source:Eurekalert  

Page: 1 2 3 4 5

Related biology news :

1. UC Davis research shows that newly discovered drug reduces heart enlargement
2. UC Davis researchers find molecule that targets brain tumors
3. UC Davis discovery offers hope for treating kidney cancer
4. UC Davis team refines cancer treatments to reduce potential nerve damage
5. UC Davis researchers exploring gene therapy to fight AIDS
6. UC Davis researchers discover Achilles heel in pancreatic cancer
7. UC Davis researchers discover a key to aggressive breast cancer
8. UC Davis chemical ecologist wins major award
9. UC Davis researchers discover new drug target for inflammatory disease
10. UC Davis researchers define characteristics, treatment options for XXYY syndrome
11. UC Davis researcher leads climate-change discovery
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UC Davis bench-to-bedside research: Promising treatment in clinical trials
(Date:11/6/2014)... Insilico Medicine, Inc, a Baltimore-based bioinformatics company focused ... announced a research collaboration with the international leader ... (OTC: CSBR). , "There are many companies utilizing ... Oncology,s TumorGraft technology is unique in a way ... generating vast amounts of valuable data. Our bioinformatic ...
(Date:11/5/2014)... Janeiro, Brazil -Individuals show great diversity in their ability ... and females greatly differ in their perceptual evaluation of ... smell tests. , Sex differences in olfactory ... and may be connected to one,s perception of smell, ... Thus, women,s olfactory superiority has been suggested to be ...
(Date:11/4/2014)... Temple University School of Medicine announced today that ... initiative funded by the Bill & Melinda Gates ... Obstetrics, Gynecology and Reproductive Sciences; and Vice Chair ... School of Medicine will pursue an innovative global ... Biomarkers to Assess Fetal Neurodevelopment.", Grand Challenges Explorations ...
Breaking Biology News(10 mins):Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2The female nose always knows: Do women have more olfactory neurons? 2Temple University School of Medicine receives Grand Challenges Explorations grant 2
... RENO, Nev. Like the little engine that could, ... sludge to electrical power is chugging along, dwarfed by ... Meadows Water Reclamation Facility where, ultimately, the plant,s electrical ... researchers are developing. "We are very pleased with ...
... French . Treatment with vitamin C rapidly ... a study carried out by researchers at Montreal,s Jewish General ... Research (LDI). In a double-blind clinical trial, patients admitted ... C or vitamin D supplements for seven to ten days. ...
... A committee of the National Academy of Engineering ... of the causes of the Deepwater Horizon explosion and ... from Mark Bly, group head of safety and operations ... released accident investigation report. Also on the agenda ...
Cached Biology News:University of Nevada, Reno demonstrates successful sludge-to-power research 2University of Nevada, Reno demonstrates successful sludge-to-power research 3Vitamin C rapidly improves emotional state of acutely hospitalized patients, say LDI researchers 2
(Date:11/26/2014)... 26, 2014 The ETC (Emerging ... technology innovation centers, announced today that applications for ... December 1st. “Do you have a big idea?,” ... want to know about it. AccelerateBaltimore helps you ... product in just 13 weeks.” Interested game ...
(Date:11/26/2014)... Whitehouse Laboratories is pleased to announce ... (New Jersey) Chamber of Commerce as a member. ... in the North Jersey area, offers Whitehouse Laboratories ... clients in the pharmaceutical and biotechnology areas that ... enables Whitehouse Laboratories a higher level of visibility ...
(Date:11/26/2014)... Sunnyvale, CA (PRWEB) November 25, 2014 ... joins forces with RPM Alliance , provider ... and pharmaceutical companies. With the latest addition to its ... only free validated EDC system to India. , ... as a robust and customizable EDC platform which is ...
(Date:11/26/2014)... 2014 The Pittcon marketing department is ... and exposition mobile app, Pittcon 2015 ... the App Store for iOS and Android devices and ... before, during and after the event. It acts as ... companies, technical sessions, Conferee Networking sessions and short courses. ...
Breaking Biology Technology:AccelerateBaltimore Applications to Close in 6 Days 2AccelerateBaltimore Applications to Close in 6 Days 3Whitehouse Laboratories Joins Morris County Chamber of Commerce 2Whitehouse Laboratories Joins Morris County Chamber of Commerce 3RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 2Pittcon Releases 2015 Mobile App 2
... Technologies, an emerging,leader in the development of implantable ... today the addition of Jon Tremmel to its,Board ... after nearly 30 years of service,Jon held a ... the,Neurological Division, President of the Physio-Control Division, President,of ...
... of promoted products and reduced operating costs drive solid ... ... WCRX ) today announced its results for the quarter ended,March 31, ... increase of 5.1%, over the prior year quarter. The primary,drivers of the ...
... ,EUSA Pharma Inc (,EUSA,), a transatlantic specialty pharmaceutical ... today announced that,it has completed its acquisition of ... a special meeting on 8 May., Under ... will,receive $0.62 per share, valuing the company at ...
Cached Biology Technology:InSet Technologies Appoints Jon Tremmel to its Board of Directors 2Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 2Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 3Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 4Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 5Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 6Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 7Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 8Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 9Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 10Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 11Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 12Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 13Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 14Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 15Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 16Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 17EUSA Pharma Completes Acquisition Of Cytogen Corporation 2EUSA Pharma Completes Acquisition Of Cytogen Corporation 3
... the yolk protein Vtg in plasma from juvenile ... biomarker for endocrine disrupting chemicals (EDCs) with estrogenic ... an accepted screening test for the estrogenic effects ... EIA kit is a double-antibody immunometric (sandwich) EIA ...
... (RTL) can provide you with the ... method development and validation ,Performance of ... of your GMP manufacturing environment ,Assurance ... a full spectrum of microbiological services ...
... PEP-152 is a 17 amino acid synthetic peptide whose sequence ... is (amino to carboxy terminus): C - N(217) - Q ... S - A - T - P - N - Y ... peptide may be used for neutralization and control experiments with the ...
... of IgY) , After we receive your antigen ... the appropriate number of chickens and begin to ... collected (usually over a period of 3-5 days), ... total of four injections into the breast muscle. ...
Biology Products: